We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Identifies Biomarker Linked to MS

By LabMedica International staff writers
Posted on 02 Sep 2009
Antibody levels in blood produced in response to Epstein Barr Virus (EBV), could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a first MS-like attack.

Investigators studied 100 individuals, 50 of whom had a single MS-like attack but no diagnosis of MS, 25 people with relapsing remitting MS, and 25 with primary progressive MS. More...
They tested the participants for evidence of EBV infection in the blood and also looked for anti-EBNA-1 Immunoglobulin G (IgG) and other EBV induced antibodies. MRI brain scans of each participant were taken over a five-year period to determine the disability progression.

EBV DNA in blood was quantified by real-time quantitative polymerase chain reaction (PCR) and EBV serology for anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG), antiviral capsid antigen (VCA) IgG, and anti-EBV IgM.

The work was performed by Dr. Rachel Farrell at the department of neuroinflammation, Institute of Neurology, University College London (UCL; London, UK) and colleagues. Dr. Farrell said, "All the participants in our study had previous history of infection with EBV, which has been shown in other studies and is not surprising given that a large majority of the adult population is infected with EB. What was surprising is that the levels of a molecule in the blood called anti-EBNA-1 IgG, induced by the virus, were associated with the activity of MS."

The study was reported in the July 2009 issue of the journal Neurology. The authors concluded that anti-EBNA-1 IgG is a potential biomarker in MS that might be useful in predicting disability and disease progression. They added that the work needed to be validated in larger studies and in combination with other yet unidentified biomarkers

Related Links:
University College London



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.